Vasectomy and prostate cancer — the debate evolves

As regular readers will be well aware, the question of whether there is a real cause and effect association between having a vasectomy and the later risk for diagnosis of prostate cancer is controversial and unanswered in any absolute sense. However, there are new data that we can now put on the table … … READ MORE …

Maybe this time … a real answer to the value of PSA screening?

We have frequently referred to an ongoing trial in the UK known as the ProtecT trial. That trial is comparing the effectiveness and safety of surgery, radiation therapy, active surveillance as treatments for well-characterized men diagnosed with localized prostate cancer … but there is something else important we hadn’t realized … … READ MORE …

Risk for 120-day prostate biopsy-specific mortality — redux

Once upon a time (not so very long ago) Boniol et al. suggested that the 120-day mortality rate associated with biopsies for risk of prostate cancer might be as high as 1.3 percent. This caused something of a furore. … READ MORE …

Visceral metastases are NOT a good thing for prostate cancer patients

In an utterly unsurprising finding reported last weekend at the ASCO meeting in Chicago, Halabi et al. reported, based on a meta-analysis of data from nearly 4,000 patients in clinical trials for late-stage prostate cancer, that having visceral (i.e., soft tissue) prostate cancer metastasis is not a good thing at all. … READ MORE …

When test “validation” raises questions about levels of validity

There is something of a fuss emerging about data presented at the American Urological Association annual meeting and a claim that these data imply that Myriad Genetics’ genomic Prolaris test ‘has been “validated” in its ability to predict disease-specific death’. … READ MORE …

The benefit (or lack thereof) of early, aggressive treatment in men ≥ 66 years

A new study published on line in the journal Cancer has shown that (a) the cancer-specific survival benefit associated with aggressive treatment for early-stage prostate cancer is reduced with increasing co-morbidity at time of diagnosis, and (b) patients with Charlson scores ≥ 3 gain no survival benefit from aggressive treatment. … READ MORE …

Gleason score and metastatic prostate cancer; risk for 4-year mortality

It is difficult to accurately interpret a set of data just published that was designed to assess the relationship between 4-year survival and Gleason score at diagnosis in men initially diagnosed with metastatic prostate cancer. … READ MORE …

Your blood type may affect your risk for prostate cancer mortality

Perhaps the most fascinating paper to be presented this year at the Genitourinary Cancers Symposium has to do with blood typing and risk for lethal prostate cancer. … READ MORE …

No decrease in mortality rate of newly diagnosed men with metastatic prostate cancer

A newly published paper in the journal Cancer has indicated that, here in the USA, although overall prostate cancer mortality has declined by ~ 40 percent during the past 25 years, there has been no significant decrease in the mortality rate among men who have evident metastatic prostate cancer at time of diagnosis. … READ MORE …

Does regional analgesia reduce risk for cancer progression when added to general anesthesia?

Based on a retrospective analysis of data from > 1,600 patients treated by radical prostatectomy at the Mayo Clinic, a newly published paper suggests that supplementing general anesthesia with regional (neuraxial) analgesia may lower risk for disease recurrence. … READ MORE …

From Amsterdam yesterday: European perspectives on the PSA screening issue

A report on the Medscape Oncology web site, published late yesterday, discusses two presentations given yesterday at the European Cancer Conference 2013, currently being held in Amsterdam. … READ MORE …

Mediterranean diet and overall mortality after diagnosis with non-metastatic prostate cancer

An article in European Urology has shown that a heart-healthy, “Mediterranean” diet lowers the overall mortality of men diagnosed with prostate cancer. However, the study also shows that this type of diet has no impact on risk for a diagnosis of advanced or lethal prostate cancer or on prostate cancer progression or prostate cancer-specific mortality after diagnosis. … READ MORE …

Finasteride prevents 30 percent of low-risk prostate cancers (with no added risk of mortality)

An article published today in the New England Journal of Medicine and based on a re-visitation of data from the Prostate Cancer Prevention Trial (PCPT) suggests that finasteride may prevent as many as 30 percent of cases of low-risk prostate cancer without any increase in mortality. … READ MORE …

How low is the risk for Gleason score progression over time?

A new study report in Cancer Research suggests that: (a) prostate cancer aggressiveness may be established when the initial tumor is formed and not alter over time; (b) active surveillance or similar monitoring strategies really are the most appropriate initial management option for men with low-grade, low-risk cancer (potentially regardless of their age at diagnosis). … READ MORE …

Non-prostate cancer-specific mortality rates in a cohort of > 3,000 patients

The issue of how long a man who is newly diagnosed with localized prostate cancer is likely to live before he dies a natural death from other causes is a crucial element in the decision whether to undergo treatment (and how aggressive that treatment may need to be). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,115 other followers